BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 25273092)

  • 1. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
    Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
    Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
    Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
    Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
    Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
    Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
    Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
    Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
    Rose WC; Marathe PH; Jang GR; Monticello TM; Balasubramanian BN; Long B; Fairchild CR; Wall ME; Wani MC
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):73-85. PubMed ID: 16228206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
    Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimyeloma activity of NK012, a micelle-forming macromolecular prodrug of SN-38, in an orthotopic model.
    Miyazaki O; Sekine K; Nakajima N; Ichimura E; Ebara K; Nagai D; Onda T; Miyakawa Y; Okamoto K; Morino T
    Int J Cancer; 2014 Jan; 134(1):218-23. PubMed ID: 23775066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
    Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
    J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
    Ko AH
    Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
    Lei S; Chien PY; Sheikh S; Zhang A; Ali S; Ahmad I
    Anticancer Drugs; 2004 Sep; 15(8):773-8. PubMed ID: 15494639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of novel 10-substituted-7-ethyl-10-hydroxycamptothecin (SN-38) prodrugs.
    Zhou M; Liu M; He X; Yu H; Wu D; Yao Y; Fan S; Zhang P; Shi W; Zhong B
    Molecules; 2014 Nov; 19(12):19718-31. PubMed ID: 25438082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
    Koizumi F; Kitagawa M; Negishi T; Onda T; Matsumoto S; Hamaguchi T; Matsumura Y
    Cancer Res; 2006 Oct; 66(20):10048-56. PubMed ID: 17047068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
    Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
    Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
    Noble CO; Krauze MT; Drummond DC; Forsayeth J; Hayes ME; Beyer J; Hadaczek P; Berger MS; Kirpotin DB; Bankiewicz KS; Park JW
    Nanomedicine (Lond); 2014 Jul; 9(14):2099-108. PubMed ID: 24494810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
    Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
    Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
    Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
    Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
    Chen PY; Ozawa T; Drummond DC; Kalra A; Fitzgerald JB; Kirpotin DB; Wei KC; Butowski N; Prados MD; Berger MS; Forsayeth JR; Bankiewicz K; James CD
    Neuro Oncol; 2013 Feb; 15(2):189-97. PubMed ID: 23262509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
    Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
    Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.